Citations

Showing 10 of 108152 citations.

Magician’s Corner: 9. Performance Metrics for Machine Learning Models
Erickson, Bradley J. , Kitamura, Felipe , Kitamura, Felipe C , Erickson, Bradley J

Mayo Clinic

Radiology: Artificial Intelligence | May 12, 2021 | Volume: 3 | Issue: 3 | Pages: e200126

10.1148/ryai.2021200126 | PMID 34136815 Get It

Stereotactic Radiosurgery for Differentiated Thyroid Cancer Brain Metastases: An International, Multicenter Study
Fribance, Sarah , Pikis, Stylianos , Lee, John Y. K. , Buch, Love, Bernstein, Kenneth , Mathieu, David , Perron, Rémi, Patel, Samir , Álvarez, Roberto Martínez , Moreno, Nuria Martínez , Lee, Cheng‐Chia , Strickland, Ben A. , Zada, Gabriel , Chang, Eric L. , Kondziolka, Douglas , Sheehan, Jason P. , Mathieu, David , Kondziolka, Douglas , Bunevičius, Adomas , Moran, Michael, Yang, Andrew I. , Liščák, Roman , Šimonová, Gabriela , Trifiletti, Daniel M. , Yang, Huai‐Che

Mayo Clinic

Thyroid® | May 12, 2021 | Volume: 31 | Issue: 8 | Pages: 1244-1252

10.1089/thy.2020.0947 | PMID 33978475 Get It

Background: Brain metastases (BM) from differentiated thyroid cancer are rare. Stereotactic radiosurgery (SRS) is commonly used for the treatment of BMs; however, the experience with SRS for thyroid cancer BMs remains limited. The goal of this international, multi-centered study was to evaluate the efficacy and safety of SRS for thyroid cancer BMs. Methods: From 10 institutions participating in the International Radiosurgery Research Foundation, we pooled patients with established papillary or follicular thyroid cancer diagnosis who underwent SRS for histologically confirmed or radiologically suspected BMs. We investigated patient overall survival (OS), local tumor control, and adverse radiation events (AREs). Results: We studied 42 (52% men) patients who underwent SRS for 122 papillary (83%) or follicular (17%) thyroid cancer BMs. The mean age at SRS was 59.86 ± 12.69 years. The mean latency from thyroid cancer diagnosis to SRS for BMs was 89.05 ± 105.49 months. The median number of BMs per patient was 2 (range: 1–10 BMs). The median SRS treatment volume was 0.79 cm 3 (range: 0.003–38.18 cm 3 ), and the median SRS prescription dose was 20 Gy (range: 8–24 Gy). The median survival after SRS for BMs was 14 months (range: 3–58 months). The OS was significantly shorter in patients harboring ≥2 BMs, when compared with patients with one BM (Log-rank = 5.452, p = 0.02). Two or more BMs (odds ratio [OR] = 3.688; confidence interval [CI]: 1.143–11.904; p = 0.03) and lower Karnofsky performance score at the time of SRS (OR = 0.807; CI: 0.689–0.945; p = 0.008) were associated with shorter OS. During post-SRS imaging follow-up of 25.21 ± 30.49 months, local failure (progression and/or radiation necrosis) of BMs treated with SRS was documented in five (4%) BMs at 7.2 ± 7.3 months after the SRS. At the last imaging follow-up, the majority of patients with available imaging data had stable intracranial disease (33%) or achieved complete (26%) or partial (24%) response. There were no clinical AREs. Post-SRS peritumoral T2/fluid attenuated inversion recovery signal hyperintensity was noted in 7% BMs. Conclusion: The SRS allows durable local control of papillary and follicular thyroid cancer BMs in the vast majority of patients. Higher number of BMs and worse functional status at the time of SRS are associated with shorter OS in patients with thyroid cancer BMs. The SRS is safe and is associated with a low risk of AREs.
Impact of Opioid Prescribing Guidelines on Postoperative Opioid Prescriptions Following Elective Spine Surgery: Results From an Institutional Quality Improvement Initiative
Krauss, William E. , Habermann, Elizabeth B. , Ubl, Daniel S. , Alvi, Mohammed Ali , Whipple, Daniel C, Glasgow, Amy E. , Bydon, Mohamad , Glasgow, Amy E. , Gazelka, Halena M. , Bydon, Mohamad , Habermann, Elizabeth , Alvi, Mohammed Ali , Glasgow, Amy E , Goyal, Anshit , Whipple, Daniel C.

Mayo Clinic

Neurosurgery | May 12, 2021 | Volume: 89 | Issue: 3 | Pages: 460-470

10.1093/neuros/nyab196 | PMID 34114041 Get It

Abstract BACKGROUND With a dramatic rise in prescription opioid use, it is imperative to review postsurgical prescribing patterns given their contributions to the opioid epidemic. OBJECTIVE To evaluate the impact of departmental postoperative prescribing guidelines on opioid prescriptions following elective spine surgery. METHODS Patients undergoing elective cervical or lumbar spine surgery between 2017 and 2018 were identified. Procedure-specific opioid prescribing guidelines to limit postoperative prescribing following neurosurgical procedures were developed in 2017 and implemented in January 2018. Preguideline data were available from July to December 2017, and postguideline data from July to December 2018. Discharge prescriptions in morphine milliequivalents (MMEs), the proportion of patients (i) discharged with an opioid prescription, (ii) needing refills within 30 d, (iii) with guideline compliant prescriptions were compared in the 2 groups. Multivariable (MV) analyses were performed to assess the impact of guideline implementation on refill prescriptions within 30 d. RESULTS A total of 1193 patients were identified (cervical: 308; lumbar: 885) with 569 (47.7%) patients from the preguideline period. Following guideline implementation, fewer patients were discharged with a postoperative opioid prescription (92.5% vs 81.7%, P < .001) and median postoperative opioid prescription decreased significantly (300 MMEs vs 225 MMEs, P < .001). The 30-d refill prescription rate was not significantly different between preguideline and postguideline cohorts (pre: 24.4% vs post: 20.2%, P = .079). MV analyses did not demonstrate any impact of guideline implementation on need for 30-d refill prescriptions for both cervical (odds ratio [OR] = 0.68, confidence interval [CI] = 0.37-1.26, P = .22) and lumbar cohorts (OR = 0.95, CI = 0.66-1.36, P = .78). CONCLUSION Provider-aimed interventions such as implementation of procedure-specific prescribing guidelines can significantly reduce postoperative opioid prescriptions following spine surgery without increasing the need for refill prescriptions for pain control.
Optic chiasm involvement in AQP-4 antibody–positive NMO and MOG antibody–associated disorder
Tajfirouz, Deena , Padungkiatsagul, Tanyatuth , Beres, Shannon , Moss, Heather E. , Pittock, Sean J. , Kunchok, Amy , Bhatti, M. Tariq , Chen, John J. , Flanagan, E P , Shah, Shailee , Pittock, S J , Pittock, Sean J , Chen, John J , Moss, Heather E , Flanagan, Eoin P.

Mayo Clinic

Multiple Sclerosis Journal | May 12, 2021 | Volume: 28 | Issue: 1 | Pages: 149-153

10.1177/13524585211011450 | PMID 33975499 Get It

Background: Optic neuritis (ON) is often the presenting symptom in inflammatory central nervous system demyelinating disorders. Objective: To compare the frequency and pattern of optic chiasm involvement in patients with aquaporin-4-immunoglobulin G (AQP4-IgG)-associated ON to patients with myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG)-associated ON. Methods: Retrospective review of all patients evaluated at Mayo Clinic, Stanford University and Ramathibodi Hospital who were found to have: (1) ON, (2) either MOG-IgG or AQP4-IgG by cell-based assay, and (3) magnetic resonance imaging (MRI) at the time of ON. MRI was reviewed for contrast enhancement of the optic chiasm and the pattern of involvement. Results: One hundred and fifty-four patients (74 AQP4-IgG and 80 MOG-IgG) were included. Among patients with AQP4-IgG-ON, 20% had chiasmal involvement, compared with 16% of patients with MOG-IgG-ON ( p = 0.66). In patients with chiasmal involvement, longitudinally extensive optic nerve enhancement (from orbit extending to chiasm) was identified in 54% of MOG-IgG-ON patients, compared with 7% of AQP4-IgG-ON patients ( p = 0.01). Conclusion: Chiasmal involvement of MOG-IgG-ON and AQP4-IgG-ON occur at more similar frequencies than previously reported. Furthermore, MOG-IgG-ON chiasmal involvement is more likely to be part of a longitudinally extensive optic nerve lesion.
Electromagnetic interference from left ventricular assist device in patients with transvenous implantable cardioverter‐defibrillator
Khetarpal, Banveet Kaur , Lee, Justin Z. , Javaid, Awad , Mi, Lanyu , Venepally, Nithin R. , Narasimhan, Bharat , Hardaway, Brian , Cha, Yong‐Mei , Kusumoto, Fred , Mulpuru, Siva K. , Hardaway, Brian W, Kusumoto, Fred M , Srivathsan, Komandoor

Mayo Clinic

Pacing and Clinical Electrophysiology | May 12, 2021 | Volume: 44 | Issue: 7 | Pages: 1163-1175

10.1111/pace.14265 | PMID 33977542 Get It

AbstractBackgroundMany advanced heart failure patients have both a left ventricular assist device (LVAD) and an implantable cardioverter‐defibrillator (ICD). This study examines incidence, clinical impact, and management of LVAD‐related EMI.MethodsWe performed a three‐center retrospective analysis of transvenous ICD implanted patients with LVAD implanted between January 1, 2005 and December 31, 2020. The primary outcome was EMI after LVAD implantation, categorized as LVAD‐related noise or telemetry interference.ResultsThe rate of LVAD‐related EMI among the 737 patients (mean age 58.6 ± 12.8 years) studied was 5.0%. Telemetry interference (1.5%) compromised ICD interrogation in all patients. This was resolved successfully with use of a metal shield, encased wand, radiofrequency tower, different ICD programmer or by increasing distance between ICD programmer and LVAD (n = 6). ICD replacement was required to reestablish successful communication in three patients. LVAD‐related noise (3.5%) led to oversensing (n = 4), inappropriate mode switches (n = 4), noise reversion (n = 3), inhibition of pacing (n = 2), inappropriate detection as atrial fibrillation (AF) (n = 2) and inappropriate detection as ventricular tachycardia (VT) and/or ventricular fibrillation (VF) (n = 2). This noise interference persisted (n = 3), resolved spontaneously (n = 16), resolved with programming change (n = 6) or required lead revision (n = 1).ConclusionsEMI from LVAD impacts ICD function, although, the incidence rate is low. Physicians implanting both, LVAD in patients with ICD (more common) or ICD in patients with LVAD, should be aware of possible interferences. Telemetry failure not resolved by metal shielding was overcome by ICD generator replacement to a different manufacturer. In most cases, LVAD‐related noise resolves spontaneously.
A rare case of childhood mucous membrane pemphigoid involving the oral and genital mucosa
Baisi, Katinna E. Rodriguez , Wentworth, Ashley B., Chattha, Asma , DiCaudo, David J. , Mangold, Aaron R. , Nelson, Steven A. , Siegfried, Elaine C. , Wieland, Carilyn N. , Tollefson, Megha M. , Rodriguez Baisi, Katinna , Wentworth, Ashley, Chattha, Asma J , Mangold, A R , Siegfried, Elaine C , Tollefson, Megha

Mayo Clinic

Pediatric Dermatology | May 12, 2021 | Volume: 38 | Issue: 4 | Pages: 904-907

10.1111/pde.14627 | PMID 33977558 Get It

AbstractMucous membrane pemphigoid (MMP) is a rare chronic immunobullous disease that involves the mucous membranes and may result in significant scarring and complications if diagnosis is delayed. MMP typically occurs in elderly patients, with very few cases reported in children. Here, we present a 12‐year‐old female patient with childhood‐onset oral and genital MMP, clinically suspected to be lichen sclerosus, but eventually diagnosed as MMP after multiple supportive biopsies and confirmatory direct immunofluorescence. Although treatment was challenging, the combined use of systemic corticosteroids, dapsone, and mycophenolate mofetil was ultimately successful in achieving disease control.
Surface Roughness of Titanium Orthopedic Implants Alters the Biological Phenotype of Human Mesenchymal Stromal Cells
Trousdale, William H. , Thaler, Roman , Xu, Wei , Denbeigh, Janet M. , Nair, Asha, Kocher, Jean‐Pierre , Dudakovic, Amel , Berry, Daniel J., Cohen, Robert C., Lewallen, David G. , Wijnen, André J. van , Berry, Daniel J. , Lewallen, Eric A. , Xu, Wei , van Wijnen, Andre J , Berry, Daniel J , Yao, Jie , Berry, Daniel J., Abdel, Matthew P.

Mayo Clinic

Tissue Engineering Part A | May 12, 2021 | Volume: 27 | Issue: 23-24 | Pages: 1503-1516

10.1089/ten.tea.2020.0369 | PMID 33975459 Get It

Recurrence of primary cutaneous CD30-positive lymphoproliferative disorder following COVID-19 vaccination
Brumfiel, Caitlin M. , Patel, Meera H. , DiCaudo, David J. , Pittelkow, Mark R. , Mangold, Aaron R. , Rosenthal, Allison , Pittelkow, Mark R , Mangold, A R

Mayo Clinic

Leukemia & Lymphoma | May 11, 2021 | Volume: 62 | Issue: 10 | Pages: 2554-2555

10.1080/10428194.2021.1924371 | PMID 33974494 Get It

Evidence-Based Health Informatics as the Foundation for the COVID-19 Response: A Joint Call for Action
Kushniruk, André, Georgiou, Andrew , Petersen, Carolyn , Ronquillo, Charlene , Paton, Chris , Nøhr, Christian , Skiba, Diane J., Huesing, Elaine, Gabarrón, Elia , Magrabi, Farah , Peute, Linda , Topaz, Max, Al-Shorbaji, Najeeb , Lacroix, Paulette, Cornet, Ronald , Gogia, Shashi Bhushan , Kobayashi, Shinji , Iyengar, Sriram , Mettler, Tobias , Vimarlund, Vivian , Petersen, Carolyn , Fernández-Luque, Luis , Basu, Arindam , Kuziemsky, Craig E. , Alhuwail, Dari , Borycki, Elizabeth M. , Denecke, Kerstin , Marcilly, Romaric , Deserno, Thomas M , Zhu, Xinxin

Mayo Clinic

Methods of Information in Medicine | May 11, 2021 | Volume: 59 | Issue: 06 | Pages: 183-192

10.1055/s-0041-1726414 | PMID 33975375 Get It

Abstract Background As a major public health crisis, the novel coronavirus disease 2019 (COVID-19) pandemic demonstrates the urgent need for safe, effective, and evidence-based implementations of digital health. The urgency stems from the frequent tendency to focus attention on seemingly high promising digital health interventions despite being poorly validated in times of crisis. Aim In this paper, we describe a joint call for action to use and leverage evidence-based health informatics as the foundation for the COVID-19 response and public health interventions. Tangible examples are provided for how the working groups and special interest groups of the International Medical Informatics Association (IMIA) are helping to build an evidence-based response to this crisis. Methods Leaders of working and special interest groups of the IMIA, a total of 26 groups, were contacted via e-mail to provide a summary of the scientific-based efforts taken to combat COVID-19 pandemic and participate in the discussion toward the creation of this manuscript. A total of 13 groups participated in this manuscript. Results Various efforts were exerted by members of IMIA including (1) developing evidence-based guidelines for the design and deployment of digital health solutions during COVID-19; (2) surveying clinical informaticians internationally about key digital solutions deployed to combat COVID-19 and the challenges faced when implementing and using them; and (3) offering necessary resources for clinicians about the use of digital tools in clinical practice, education, and research during COVID-19. Discussion Rigor and evidence need to be taken into consideration when designing, implementing, and using digital tools to combat COVID-19 to avoid delays and unforeseen negative consequences. It is paramount to employ a multidisciplinary approach for the development and implementation of digital health tools that have been rapidly deployed in response to the pandemic bearing in mind human factors, ethics, data privacy, and the diversity of context at the local, national, and international levels. The training and capacity building of front-line workers is crucial and must be linked to a clear strategy for evaluation of ongoing experiences.
l-Arginine Can Enhance the Beneficial Effect of Losartan in Patients with Chronic Aortic Regurgitation and Isolated Systolic Hypertension
Lin, Shoa-Lin, Lin, Mike, Wang, Kuei-Liang, Kuo, Hsien‐Wen , Tak, Tahir , Lin, Shoa-Lin, Wang, Kuei-Liang

Mayo Clinic

International Journal of Angiology | May 11, 2021 | Volume: 30 | Issue: 02 | Pages: 122-131

10.1055/s-0041-1723948 | PMID 34054270 Get It

AbstractInformation about the effects of angiotensin II receptor blocker (ARB) therapy on the hemodynamic and cardiac structure in patients with chronic aortic regurgitation (CAR) and isolated systolic hypertension (ISH) is limited.This study planned to test the hypothesis that l-arginine could further enhance the beneficial effect of an ARB, losartan, and provide a favorable effect on the natural history of CAR and ISH.Sixty patients with CAR and ISH were enrolled in a randomized, double-blind trial comparing hemodynamic and ultrasonic change in two treatment arms: losartan + l-arginine and losartan-only treated groups. Serial echocardiographic and hemodynamic studies were evaluated before and after treatment.Both groups had a significant reduction in systolic blood pressure (SBP) and diastolic blood pressure (DBP), left ventricular end-diastolic volume index (LVEDVI), LV end-systolic volume index (LVESVI), LV mass index (LVMI), and LV mean wall stress after 6- and 12-month treatment (p <0.01 in all comparisons). Both groups had a significant increase in LV ejection fraction and exercise duration after 6- and 12-month treatment (p < 0.01 in all comparisons). Using multivariate linear regression analysis, only losartan + l-arginine therapy achieved a significantly lower LVESVI (38.89 ± 0.23 mL/m2), LVEDVI (102.3 ± 0.3 mL/m2), LVMI (107.6 ± 0.3 g/m2), SBP (123.5 ± 1.0 mm Hg), and greater exercise duration (7.38 ± 0.02 minutes) than those of the losartan-only treated groups (p <0.01 in all comparisons).These findings suggest that early co-administrative strategy provides a beneficial approach to favorably influence the natural history of CAR.